Comparative Pharmacology
Head-to-head clinical analysis: NATAZIA versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATAZIA versus NORTREL 1 35 21.
NATAZIA vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal half-life approximately 30 hours for drospirenone and 24 hours for ethinyl estradiol; steady-state achieved within 8–10 days.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Fecal excretion is the primary route (approximately 68%), with renal excretion accounting for about 27% (mostly as metabolites).
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive